Media Advisory
Friday, April 17, 2020
Vaccine reduces the effects of several MERS-CoV stress.
Colorized transmission electron micrograph revealing particles of the Middle East Breathing Syndrome Coronavirus that emerged in2012 NIAID
What
An investigational vaccine called ChAdOx1 MERS safeguarded two groups of rhesus macaques from illness caused by Middle East respiratory syndrome coronavirus (MERS-CoV). MERS-CoV is a relative of the serious acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19). National Institutes of Health researchers and coworkers are pursuing comparable studies with ChAdOx1 SARS2, a vaccine prospect versus SARS-CoV-2. They published their results with ChAdOx1 MERS on a preprint server. The findings are not yet peer-reviewed but are being shared to assist the public health action to COVID-19
ChAdOx1 MERS, which utilizes a replication-deficient chimpanzee adenovirus to provide a MERS-CoV protein in recipients, also worked against six different stress of MERS-CoV when evaluated in mice as a single vaccination. Researchers from NIH’s National Institute of Allergy and Infectious Illness (NIAID) at Rocky Mountain Laboratories in Hamilton, Mont., led the task. Partners work at the University of Oxford in the United Kingdom; researchers at the University of Oxford Jenner Institute developed the ChAdOx1 vaccine innovation.
MERS-CoV triggers disease deep in the lungs, leading to pneumonia among contaminated people.
In the macaque research study, one group of animals was immunized 28 days prior to infection; the other group got 2 vaccinations– a prime-boost strategy–56 and 28 days prior to infection. A third group of monkeys functioned as controls. The scientists report that none of the animals in the two treatment groups developed indications of MERS-CoV illness. The prime-boost group clearly had less infection in lung tissue compared to the control group and no evidence of replicating virus, while the prime-only group showed much less virus in tissue than the control group. Both treatment groups revealed no lung damage and were safeguarded from illness, unlike the control animals.
The scientists’ MERS-CoV macaque research study follows earlier research studies of the speculative vaccine in mice. They also have effectively tested the vaccine platform against Nipah virus in hamsters and versus Lassa virus in guinea pigs; they next plan to expedite checking a vaccine candidate against SARS-CoV-2.
The MERS vaccine is being studied in Phase 1 human scientific trials in the United Kingdom and Saudi Arabia. The very same chimpanzee adenovirus vaccine platform likewise is being examined for malaria, HIV, influenza, hepatitis C, tuberculosis and Ebola.
Article
N van Doremalen et al A single dose of ChAdOx1 MERS offers broad protective resistance versus a variety of MERS-CoV stress.
Who
Vincent Munster, Ph.D., and Marshall Flower, M.D., of NIAID’s Lab of Virology, are readily available to comment on this research study.
NIAID conducts and supports research– at NIH, throughout the United States, and worldwide– to study the reasons for infectious and immune-mediated diseases, and to develop better ways of avoiding, diagnosing and treating these health problems. News releases, truth sheets and other NIAID-related products are available on the NIAID website.
About the National Institutes of Health (NIH):
NIH, the nation’s medical research firm, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Being Services. NIH is the primary federal firm carrying out and supporting fundamental, clinical, and translational medical research study, and is investigating the causes, treatments, and cures for both common and uncommon illness. For more details about NIH and its programs, go to www.nih.gov.
NIH … Turning Discovery Into Health ®
###
